Mauro Chies
Mauro Chies is the Chief Executive Officer of the pan-Canadian Pharmaceutical Alliance (pCPA), an organization that negotiates drug prices on behalf of federal and provincial public insurance plans in Canada. Under his leadership, the pCPA has saved considerable amounts in drug spending through collective negotiations with pharmaceutical manufacturers. Chies has expressed concerns that new pricing policies from the U.S. could lead to higher drug prices in Canada, potentially straining the healthcare system.
Not in the pool (under ¢1).
Recent news mentions
Mauro Chies, chief executive officer of the pCPA, said the pCPA is prioritizing the Project Orbis cancer drugs already in its pipeline.
Ontario pilot project allows faster-than-usual public coverage of five cancer drugs
Canada· 2026-01-22
Chief executive officer Mauro Chies said in a statement that drug price negotiations are confidential as agreed upon by both the pCPA and the manufacturers.
U.S. pushes drugmakers to reveal confidential details of contracts with Canada, other countriesCanada· 2025-11-11
Mauro Chies is the chief executive officer of the pCPA and emphasizes the importance of negotiations.
Myeloma patients launch campaign advocating for immunotherapy pricing talks to resumeCanada· 2025-11-03
Mauro Chies, chief executive officer of the pCPA, said the goal is for pricing negotiations to run over three or four months.
Ontario to offer early access to some new cancer drugs in pilot projectCanada· 2025-10-07
Mauro Chies, chief executive officer of the pCPA, said he expects pharmaceutical companies to honour the pricing terms on existing agreements.
Trump says new order will lower U.S. drug prices and increase them everywhere elseCanada· 2025-05-13
